Clinical trials: Human Immunodeficiency Virus Type 1
HIV-1-infection
Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women
An Open Label randomized control study. To explore the safety of Truvada when used as PrEP during pregnancy and lactation. Pregnant women considered at risk for HIV infection and willing to participate in this randomized control…
- Trial name
- PrEP (NCT03227731)
- Testing
- Truvada
- Where
- South Africa
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- University of KwaZulu
HIV Infections, HIV-1-infection
HIV Drug Resistance Pattern Due to Migration in Poland
According to the Polish governmental statistics migration of people from Ukraine to Poland is growing and only in year 2020 have come to Poland about a quarter of a million of Ukrainian migrants.
- Conditions
- HIV Infections, HIV-1-infection, Resistant Infection
- Trial name
- NCT04636736
- Testing
- HIV drug resistance testing
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Warsaw
HIV-1
A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care
The purpose of this study is to assess the efficacy of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) fixed-dose combination (FDC) in a Test and Treat model of care in newly diagnosed human…
- Trial name
- NCT03227861
- Testing
- DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
- Where
- 16 sites in United States
- Volunteers
- 109 people
- Sponsor
- Janssen Scientific Affairs, LLC
HIV Infections
Anti-HIV Activity and Safety of 3 Different Doses of Mifepristone in HIV Infected People
The purpose of this study is to determine the anti-HIV activity and safety of 3 different doses of mifepristone (also known as VGX-410 and RU486) in HIV infected people.
- Trial name
- NCT00099645
- Testing
- Mifepristone
- Where
- 10 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-I, Human Immunodeficiency Virus Type 1
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
This study will evaluate whether oral islatravir (ISL) is effective in preventing Human Immunodeficiency Virus Type 1 (HIV-1) infection in women at high-risk for HIV-1 infection.
- Conditions
- HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis
- Trial name
- Impower-022 (NCT04644029)
- Testing
- Islatravir, FTC/TDF
- Where
- 24 sites in United States, South Africa and 1 more
- Volunteers
- 730 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1 Infection
Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis
The purpose of this study was to see which one of two medicines (topical gentian violet [GV] or nystatin oral suspension) was better than the other in treating Oral Candidiasis (OC).
- Trial name
- NCT01427738
- Testing
- Gentian Violet, Nystatin oral suspension
- Where
- 10 sites in Botswana, India and 5 more
- Volunteers
- 221 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV-1-infection
Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N
HIV-1 infected subjects that experience virological failure while on non nucleoside reverse-transcriptase inhibitors (NNRTIs), including those with the K103N mutation, are usually switched to a boosted Protease Inhibitor…
- Trial name
- WISARD (NCT05349838)
- Testing
- Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy
- Where
- 29 sites in Belgium, France and 4 more
- Volunteers
- 140 people
- Sponsor
- NEAT ID Foundation
HIV-1-infection
Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus
The primary objective of this study is to evaluate the short-term antiviral potency of GS-9131 functional monotherapy compared to placebo-to-match (PTM) GS-9131, each administered once daily with the existing failing…
- Trial name
- NCT03472326
- Testing
- GS-9131, BIC, TAF
- Where
- 2 sites in Uganda, Zimbabwe
- Volunteers
- 21 people
- Sponsor
- Gilead Sciences
HIV Seropositive
Study of Vitamin D Supplementation to Male HIV Sero-positive Patients
The investigators want to investigate if HIV sero-positive males benefit from vitamin D supplementation. The study runs in 16 weeks and the participants are treated with one of three placebo controlled regimes (tablets): 1.
- Trial name
- NCT00990678
- Testing
- Rocaltrol, Vitamin D, Calcium
- Where
- Denmark
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
HIV Infections, Pneumococcal Infections
Safety of and Immune Response to a Pneumococcal Vaccine (PncCV) in HIV Infected and Uninfected Children
Infection by Streptococcal pneumoniae is a common invasive bacterial infection in HIV infected children. The purpose of this study is to determine the safety of and immune response to a pneumococcal polysaccharide-protein…
- Trial name
- NCT00099658
- Testing
- Pneumococcal polysaccharide-protein conjugate vaccine
- Volunteers
- 579 people, healthy volunteers welcome
- Sponsor
- CIPRA SA
Human Immunodeficiency Virus
Problems With Immune Recovery in the Gut Tissue
The aim of this study is to find out if the process of HIV replication in the lymph tissue and gut tissue of people taking HIV drugs causes long-term damage to the ability of the gut to protect you from other infections and…
- Trial name
- NCT01460433
- Testing
- Genital and rectal swabbing
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
HIV Infections
Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs
The purpose of this study is to determine the safety of a single, under-the-skin dose of interleukin-7 (IL-7) in HIV infected people currently taking anti-HIV drugs.
- Trial name
- NCT00099671
- Testing
- Recombinant human interleukin-7
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals
TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC-07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry.
- Trial name
- NCT05275998
- Testing
- TMB-365/TMB-380
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- TaiMed Biologics Inc.
HIV Infections, Hemophilia A
Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
The purpose of this study is to see if indinavir plus two other anti-HIV drugs affect blood clotting in HIV-positive patients with hemophilia.
- Trial name
- NCT00002386
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 8 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus Type 1
A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines
The purpose of this study is to evaluate the dose-response relationship of antiviral activity after 48 weeks treatment with 3 different dose regimens of TMC278.
- Trial name
- NCT00110305
- Testing
- TMC278 25 mg, TMC278 75 mg, TMC278 150 mg
- Where
- 40 sites in United States, Argentina and 12 more
- Volunteers
- 368 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV-1-infection, Alcohol Drinking
Acceptance and Commitment Therapy for HIV+ Hazardous Drinkers
Alcohol consumption is a critical factor in HIV treatment that significantly contributes to poor treatment-related outcomes. Randomized clinical trials (RCTs) of alcohol interventions for people with HIV (PWH) have had limited…
- Trial name
- NCT06648629
- Testing
- Acceptance and Commitment Therapy (ACT), Brief Alcohol Intervention
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Syracuse University
HIV Infection
Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)
As a measure of secondary prophylaxis, and with the final objective of avoiding the infection, it has been suggested to use antiretroviral therapy. This is known as post-exposure prophylaxis (PEP).
- Trial name
- RAL-PEP (NCT01576731)
- Testing
- Tenofovir, Emtricitabine, Lopinavir/r, Tenofovir, Emtricitabine, Raltegravir
- Where
- Spain
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
HIV Infection
Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth
This protocol is a study of HIV+ young people who were identified as having certain HIV-1 specific T-cell responses and genetic markers while previously enrolled in the 5-year longitudinal adolescent study, "REACH." Blood samples…
- Trial name
- NCT00107029
- Where
- 10 sites in United States
- Volunteers
- 113 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infection
TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use
The purpose of this study is to determinate the effectiveness, safety and tolerability (how well the body accepts the drug) of an investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) called TMC125.
- Trial name
- NCT00225303
- Testing
- TMC125
- Volunteers
- 116 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV-1-infection, Metabolic Syndrome
Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen
Switching patients with HIV infection from tenofovir disoproxil fumarate (TDF) to a tenofovir alafenamide (TAF) based drug regimen can provide many safety benefits including preserving bone mineral density and kidney function.
- Conditions
- HIV-1-infection, Metabolic Syndrome, Cardiovascular Diseases, Weight Gain
- Trial name
- NCT03646370
- Testing
- Tenofovir Alafenamide
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Thomas Jefferson University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.